Biodosimetry, can it find its way to the nuclear medicine clinic?

Frontiers in Nuclear Medicine

Nuclear Medicine

Charlot Vandevoorde¹  Stuart More²  Nastassja Combrink³  Kaat Spoormans⁴  Randall Fisher⁵  Julie Bolcaen⁵  Janke Kleynhans⁶ 

[1] Biophysics Departement, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany;Division of Nuclear Medicine, Department of Radiation Medicine, University of Cape Town, Cape Town, South Africa;Nuclear Medicine Division, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa;Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University of Leuven, Leuven, Belgium;Radiation Biophysics Division, SSC Laboratory, iThemba Laboratory for Accelerator Based Sciences (iThemba LABS), Cape Town, South Africa;Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, Catholic University of Leuven, Leuven, Belgium;

关键词: [Lu]Lu-PSMA-RLT;    [Lu]Lu-DOTA-TATE/TOC;    Iodine-131;    dicentric chromosome assay (DCA);    γH2AX foci assay;    cytokinesis-block micronucleus assay (CBMN);    gene transcript analysis;    biodosimetry and nuclear medicine;   

DOI  :  10.3389/fnume.2023.1209823

 received in 2023-04-21, accepted in 2023-07-06,  发布年份 2023

来源: Frontiers

【 摘 要 】

Personalised dosimetry based on molecular imaging is a field that grew exponentially in the last decade due to the increasing success of Radioligand Therapy (RLT). Despite advances in image-based 3D dose estimations, the administered dose of a therapeutic radiopharmaceutical for RLT is often non-personalized, with standardised dose regimes administered every 4–6 weeks. Biodosimetry markers, such as chromosomal aberrations, could be used alongside image-based dosimetry as a tool for individualised dose estimations to further understand normal tissue toxicity and refine the administered dose. In this review we give an overview of biodosimetry markers that are used for blood dose estimations, followed by an overview of their current results when applied in RLT patients. Finally, an in-depth discussion will give a perspective on the potential for the use of biodosimetry in the nuclear medicine clinic.

【 授权许可】

Unknown   
© 2023 Bolcaen, Combrink, Spoormans, More, Vandevoorde, Fisher and Kleynhans.